rocketchoo2的个人主页 - 老虎社区

rocketchoo2

rocketchoo2

暂无个人介绍

IP属地：未知

41关注

4粉丝

0主题

0勋章

2021-07-23

$Gaotu Techedu Inc.(GOTU)$Can't even describe how I feel now. :( X 10000000

2021-11-18

Finally!!! Its time for it to shine!

Novavax shares jumped 5% in premarket trading

2021-12-19

Nova!!!!

Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade

2021-06-04

$Tiger Brokers(TIGR)$Thank you. Thank you.

2021-12-27

Yes pleaseeeeeee.

Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla

2021-11-30

Vaccine stock rally tonight 🔥🙏💉

抱歉，原内容已删除

2021-06-23

$Stem Inc.(STEM)$[财迷] [财迷] [财迷]

2021-11-19

Holding on....especially with the opening of themeparks in the near future.

抱歉，原内容已删除

2021-09-09

$Tiger Brokers(TIGR)$waiting for report to be released tmr. Hang in there! [吃瓜]

2021-12-19

Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?

Why Pfizer and Johnson & Johnson Fell on Friday

2021-09-02

$Tesla Motors(TSLA)$[财迷]

2021-07-14

$Stem Inc.(STEM)$T.T from +25% profit to loss in a week. Ouchhhhhh.

2021-12-24

Another great yr for pfizer!?

Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.

2021-12-24

Yes. Continue to rallllllyyyyy

抱歉，原内容已删除

2021-12-17

Good read!

Why analysts love Apple right now

2021-12-20

Bookmark this

抱歉，原内容已删除

2021-12-20

Please huat nova.

Biden to deliver Tuesday speech on Omicron variant amid COVID rise

2021-09-09

$Tesla Motors(TSLA)$[财迷]

2021-09-02

More more more

2021-06-17

$ChargePoint Holdings Inc.(CHPT)$lets do it!

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574086622886620","uuid":"3574086622886620","gmtCreate":1614185144348,"gmtModify":1622818829225,"name":"rocketchoo2","pinyin":"rocketchoo2","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":41,"tweetSize":21,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.14%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":696300104,"gmtCreate":1640612840415,"gmtModify":1640612840516,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Yes pleaseeeeeee.","listText":"Yes pleaseeeeeee.","text":"Yes pleaseeeeeee.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696300104","repostId":"1111088353","repostType":4,"repost":{"id":"1111088353","kind":"news","pubTimestamp":1640610579,"share":"https://www.laohu8.com/m/news/1111088353?lang=&edition=full","pubTime":"2021-12-27 21:09","market":"us","language":"en","title":"Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=1111088353","media":"Seeking Alpha","summary":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems ","content":"<p><b>Summary</b></p>\n<ul>\n <li>The stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.</li>\n <li>The stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.</li>\n <li>Plug Power shows some important parallels with Tesla, on which I will elaborate in this article.</li>\n <li>If the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80405c7f3988b402597ce18944c15c47\" tg-width=\"1536\" tg-height=\"683\" width=\"100%\" height=\"auto\"><span>http://www.fotogestoeber.de/iStock via Getty Images</span></p>\n<p>How can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.</p>\n<p>In this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).</p>\n<p><b>Great stock performance, but a lofty valuation</b></p>\n<p>Plug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the&nbsp;2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.</p>\n<p>More recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the&nbsp;Build Back Better Plan&nbsp;of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.</p>\n<p>Please review the following charts for illustration of these metrics:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3664f73c0fc1fcd1b2673c8df4701be5\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Plug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)</i></p>\n<p>A true story stock</p>\n<blockquote>\n A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)\n</blockquote>\n<p>A story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.</p>\n<p>Hydrogen is indeed a promising market. Let us explore the&nbsp;potential benefits and promises&nbsp;of hydrogen:</p>\n<ul>\n <li>Green hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.</li>\n <li>Green hydrogen can contribute to improvements in air quality and energy security.</li>\n <li>Hydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.</li>\n <li>Hydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.</li>\n <li>Clean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.</li>\n <li>Currently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.</li>\n</ul>\n<p>As such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.</p>\n<p>Plug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which&nbsp;could transition&nbsp;from a story stock to a large positive cash flow company.</p>\n<p>The commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with&nbsp;Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and&nbsp;Brookfield Renewable(BEP).</p>\n<p><b>Parallels with early-stage Tesla</b></p>\n<p>I think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.</p>\n<p>Let us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9911b4514f3c0a566dffcd28c188e1c\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Tesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)</i></p>\n<p>There are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d46be5e658002b2f45b8c5ca43559b93\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Tesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)</i></p>\n<p>These two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d29232b1b3d9ff99e1edb6e4eac33901\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Development of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)</i></p>\n<p>As the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.</p>\n<p>The million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.</p>\n<p>Another similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well&nbsp;in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.</p>\n<p><b>Currently, expectations still beat metrics</b></p>\n<p>Like Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. This<i>could</i>mean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.</p>\n<p><b>These are some very large ifs.</b></p>\n<p>Of course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.</p>\n<p>Plug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.</p>\n<p>Plug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.\nThe stock performance of almost 2,000% over...</p>\n\n<a href=\"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源"},"source_url":"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111088353","content_text":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.\nThe stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.\nPlug Power shows some important parallels with Tesla, on which I will elaborate in this article.\nIf the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.\n\nhttp://www.fotogestoeber.de/iStock via Getty Images\nHow can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.\nIn this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).\nGreat stock performance, but a lofty valuation\nPlug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the 2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.\nMore recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the Build Back Better Plan of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.\nPlease review the following charts for illustration of these metrics:\nData by YCharts\nPlug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)\nA true story stock\n\n A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)\n\nA story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.\nHydrogen is indeed a promising market. Let us explore the potential benefits and promises of hydrogen:\n\nGreen hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.\nGreen hydrogen can contribute to improvements in air quality and energy security.\nHydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.\nHydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.\nClean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.\nCurrently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.\n\nAs such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.\nPlug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which could transition from a story stock to a large positive cash flow company.\nThe commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and Brookfield Renewable(BEP).\nParallels with early-stage Tesla\nI think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.\nLet us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:\nData by YCharts\nTesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)\nThere are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:\nData by YCharts\nTesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)\nThese two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:\nData by YCharts\nDevelopment of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)\nAs the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.\nThe million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.\nAnother similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.\nCurrently, expectations still beat metrics\nLike Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. Thiscouldmean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.\nThese are some very large ifs.\nOf course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.\nPlug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.\nPlug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698145843,"gmtCreate":1640327029733,"gmtModify":1640327659820,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Another great yr for pfizer!?","listText":"Another great yr for pfizer!?","text":"Another great yr for pfizer!?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698145843","repostId":"1110395878","repostType":4,"repost":{"id":"1110395878","kind":"news","pubTimestamp":1640310818,"share":"https://www.laohu8.com/m/news/1110395878?lang=&edition=full","pubTime":"2021-12-24 09:53","market":"us","language":"en","title":"Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1110395878","media":"Barrons","summary":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over","content":"<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p>\n<p>The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p>\n<p>The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p>\n<p>The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p>\n<p>As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p>\n<p>Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.</p>\n<p>And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.</p>\n<p>The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p>\n<p>The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p>\n<p>Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 09:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used ...</p>\n\n<a href=\"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110395878","content_text":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.\nThe Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.\nThe authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.\nAs Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.\nInvestors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.\nAnd the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.\nThe good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.\nThe FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.\nEarlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.","news_type":1},"isVote":1,"tweetType":1,"viewCount":729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698142420,"gmtCreate":1640326890164,"gmtModify":1640327613911,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Yes. Continue to rallllllyyyyy","listText":"Yes. Continue to rallllllyyyyy","text":"Yes. Continue to rallllllyyyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698142420","repostId":"1183390970","repostType":4,"repost":{"id":"1183390970","kind":"news","pubTimestamp":1640313641,"share":"https://www.laohu8.com/m/news/1183390970?lang=&edition=full","pubTime":"2021-12-24 10:40","market":"us","language":"en","title":"Apple Stock: Wall Street Lines Up Behind $3 Trillion Bull Case","url":"https://stock-news.laohu8.com/highlight/detail?id=1183390970","media":"TheStreet","summary":"Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side t","content":"<p>Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side takes and assess if now is the time to buy the dip in AAPL.</p>\n<p>Apple stock&nbsp;has bounced up and down in the past couple of weeks and now trades around $8 per share below&nbsp;my recent “trim the position” price point. But lack of momentum has not fazed Wall Street analysts, who increasingly believe that Apple will reach a market cap above $3 trillion within the next 12 months.</p>\n<p>Today, the Apple Maven scans through the most recently published sell-side reports and assesses the ever-stronger bull case on shares of the Cupertino company.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b8dea165a4c3f8375b37ab1560d20bec\" tg-width=\"1240\" tg-height=\"930\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple's store in New York, NY.</span></p>\n<p><b>Wall Street moves up the bar</b></p>\n<p>Because Apple stock rallied as strongly as it did in late November and early December, something unique happened: despite Wall Street having a consensus “strong buy” rating on shares, the average target price had fallen below AAPL’s market value.</p>\n<p>One of two things could have happened: either analysts would need to downgrade their views based on stretched valuations, or raise their price targets to catch up. The latter ended up happening, which suggests confidence in further upside opportunity.</p>\n<p>Last week,we pointed out that a wave of analysts&nbsp;had made their case for AAPL at a $3 trillion market cap or above. On the buy side, Gene Munster from Loup Ventures even called for $4 trillion fair value on the back of opportunities in metaverse and autonomous vehicles.</p>\n<p>The most recent report&nbsp;came in&nbsp;from Citi, on December 22. Analyst Jim Suva raised his price target by $30 to $200, citing a few positive developments ahead: (1) resilient demand for products and services in the current fiscal year; and (2) the mixed reality opportunity not fully reflected in the stock price.</p>\n<p>The bottom line is that Wall Street is looking past the short-term headwinds that have pushed AAPL share price from $180 two weeks ago to the high $160s recently. Bearish pressures, it seems, have served as a catalyst to buy Apple stock cheaper, according to analysts.</p>\n<p><b>Is it time to buy AAPL?</b></p>\n<p>Late last week,I offered a plan of action&nbsp;for those looking to buy the dip in Apple stock. First, I still think that AAPL is a good addition to a growth portfolio that does not have any exposure to it. Otherwise, I believe that investors should:</p>\n<ul>\n <li>Consider accumulating AAPL if the stock underperforms the Nasdaq by 5 percentage points — which I estimated could happen at $160 share price.</li>\n <li>“Back up the truck” in the more unlikely scenario of a share price dip below $150.</li>\n</ul>\n<p>The chart below shows that, premarket on December 22, AAPL had trailed the Nasdaq index by about 2 percentage points since my “trim the position” article. Therefore, the case for buying AAPL is slowly gaining strength, but some underperformance ahead is still not out of question.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/67f898e47d3d3dcee96368c621537b62\" tg-width=\"1095\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Figure 2: AAPL and IXIC performance.</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Wall Street Lines Up Behind $3 Trillion Bull Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Wall Street Lines Up Behind $3 Trillion Bull Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/news/apple-stock-wall-street-lines-up-behind-3-trillion-bull-case><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side takes and assess if now is the time to buy the dip in AAPL.\nApple stock has bounced up and down in ...</p>\n\n<a href=\"https://www.thestreet.com/apple/news/apple-stock-wall-street-lines-up-behind-3-trillion-bull-case\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/news/apple-stock-wall-street-lines-up-behind-3-trillion-bull-case","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183390970","content_text":"Wall Street continues to support the bull case on Apple stock. We review the most recent sell-side takes and assess if now is the time to buy the dip in AAPL.\nApple stock has bounced up and down in the past couple of weeks and now trades around $8 per share below my recent “trim the position” price point. But lack of momentum has not fazed Wall Street analysts, who increasingly believe that Apple will reach a market cap above $3 trillion within the next 12 months.\nToday, the Apple Maven scans through the most recently published sell-side reports and assesses the ever-stronger bull case on shares of the Cupertino company.\nFigure 1: Apple's store in New York, NY.\nWall Street moves up the bar\nBecause Apple stock rallied as strongly as it did in late November and early December, something unique happened: despite Wall Street having a consensus “strong buy” rating on shares, the average target price had fallen below AAPL’s market value.\nOne of two things could have happened: either analysts would need to downgrade their views based on stretched valuations, or raise their price targets to catch up. The latter ended up happening, which suggests confidence in further upside opportunity.\nLast week,we pointed out that a wave of analysts had made their case for AAPL at a $3 trillion market cap or above. On the buy side, Gene Munster from Loup Ventures even called for $4 trillion fair value on the back of opportunities in metaverse and autonomous vehicles.\nThe most recent report came in from Citi, on December 22. Analyst Jim Suva raised his price target by $30 to $200, citing a few positive developments ahead: (1) resilient demand for products and services in the current fiscal year; and (2) the mixed reality opportunity not fully reflected in the stock price.\nThe bottom line is that Wall Street is looking past the short-term headwinds that have pushed AAPL share price from $180 two weeks ago to the high $160s recently. Bearish pressures, it seems, have served as a catalyst to buy Apple stock cheaper, according to analysts.\nIs it time to buy AAPL?\nLate last week,I offered a plan of action for those looking to buy the dip in Apple stock. First, I still think that AAPL is a good addition to a growth portfolio that does not have any exposure to it. Otherwise, I believe that investors should:\n\nConsider accumulating AAPL if the stock underperforms the Nasdaq by 5 percentage points — which I estimated could happen at $160 share price.\n“Back up the truck” in the more unlikely scenario of a share price dip below $150.\n\nThe chart below shows that, premarket on December 22, AAPL had trailed the Nasdaq index by about 2 percentage points since my “trim the position” article. Therefore, the case for buying AAPL is slowly gaining strength, but some underperformance ahead is still not out of question.\nFigure 2: AAPL and IXIC performance.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693025877,"gmtCreate":1639939479267,"gmtModify":1639939479362,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Bookmark this","listText":"Bookmark this","text":"Bookmark this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693025877","repostId":"2192597562","repostType":4,"repost":{"id":"2192597562","kind":"highlight","pubTimestamp":1639752981,"share":"https://www.laohu8.com/m/news/2192597562?lang=&edition=full","pubTime":"2021-12-17 22:56","market":"us","language":"en","title":"Top 10 Metaverse Stocks in META, the World's First Metaverse ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2192597562","media":"Motley Fool","summary":"The Roundhill Ball Metaverse ETF's five largest holdings are Nvidia, Roblox, Microsoft, Meta Platforms, and Unity Software.","content":"<p>Investors are abuzz about the metaverse. This term catapulted into the mainstream in late October when the social media giant formerly known as Facebook announced it was changing its corporate name to <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a></b> (NASDAQ:FB) to reflect its focus on the metaverse.</p>\n<p>The metaverse, which is essentially a melding of the physical and virtual worlds, is widely viewed as the next evolution of the internet. Market size projections for the metaverse vary widely, so suffice it to say this space is poised to be massive.</p>\n<p>Let's take a look at the <b><a href=\"https://laohu8.com/S/META\">Roundhill Ball Metaverse ETF</a> </b>(NYSEMKT:META), the world's first metaverse exchange-traded fund (ETF). You might decide that one or more of this ETF's holdings are worth further exploration or that you want to buy the ETF itself.</p>\n<h2>Roundhill Ball Metaverse ETF: Performance and the basics</h2>\n<p>This ETF only began trading on June 30, 2021, so it's too soon to make any judgments about its performance. That said, since its inception, it's down 2.1% through Dec. 16. This performance lags that of the broader market, as the <b>S&amp;P 500 </b>index has returned 9.5% and the tech-heavy <b>Nasdaq Composite</b> has gained 4.7% over this period.</p>\n<p>The Roundhill Ball Metaverse ETF is an index fund that's designed to track the performance of the Ball Metaverse Index, which consists of a portfolio of worldwide companies involved in the metaverse. It had 40 holdings as of Dec. 16. The fund is rebalanced quarterly and has an expense ratio of 0.75%, which is moderately reasonable.</p>\n<p>This ETF is far from a pure play on the metaverse, as its holdings are mostly huge companies that are involved in multiple businesses.</p>\n<h2>Roundhill Ball Metaverse ETF: Top 10 stock holdings</h2>\n<table>\n <thead>\n  <tr>\n   <th><p><b>Holding No.&nbsp;</b></p></th>\n   <th><p><b>&nbsp;Company</b></p></th>\n   <th><p><b>Market Cap&nbsp;</b></p></th>\n   <th><p>Wall Street's Projected Annualized EPS Growth Over Next 5 Years</p></th>\n   <th><p><b>Weight (% of Portfolio)</b></p></th>\n   <th><p><b>YTD 2021 Return&nbsp;</b></p></th>\n  </tr>\n </thead>\n <thead></thead>\n <tbody>\n  <tr>\n   <td width=\"101\"><p>1</p></td>\n   <td width=\"198\"><p><b>Nvidia </b>(NASDAQ:NVDA)</p></td>\n   <td width=\"108\"><p>$710 billion</p></td>\n   <td>39.4%</td>\n   <td width=\"102\"><p>10.6%</p></td>\n   <td width=\"108\"><p>118%</p></td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>2</p></td>\n   <td width=\"198\"><p><b>Roblox </b>(NYSE:RBLX)</p></td>\n   <td width=\"108\"><p>$55 billion</p></td>\n   <td>N/A</td>\n   <td width=\"102\"><p>8.6%</p></td>\n   <td width=\"108\"><p>N/A*</p></td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>3</p></td>\n   <td width=\"198\"><p><b>Microsoft </b>(NASDAQ:MSFT)</p></td>\n   <td width=\"108\"><p>$2.4 trillion</p></td>\n   <td>16.5%</td>\n   <td width=\"102\">7.7%</td>\n   <td width=\"108\">47.3%</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>4</p></td>\n   <td width=\"198\"><p><b>Meta Platforms</b></p></td>\n   <td width=\"108\"><p>$932 billion</p></td>\n   <td>21.4%</td>\n   <td width=\"102\">6.6%</td>\n   <td width=\"108\">22.6%</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>5</p></td>\n   <td width=\"198\"><p><b>Unity Software </b>(NYSE:U)</p></td>\n   <td width=\"108\"><p>$38 billion</p></td>\n   <td>N/A</td>\n   <td width=\"102\">4.9%</td>\n   <td width=\"108\">(13%)</td>\n  </tr>\n  <tr>\n   <td><p>6</p></td>\n   <td><p><b>Apple</b></p></td>\n   <td>$2.8 trillion</td>\n   <td>15.7%</td>\n   <td>4.2%</td>\n   <td>30.6%</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>7</p></td>\n   <td width=\"198\"><p><b>Amazon.com</b></p></td>\n   <td width=\"108\"><p>$1.7 trillion</p></td>\n   <td>36%</td>\n   <td width=\"102\">4.2%</td>\n   <td width=\"108\">3.7%</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>8</p></td>\n   <td width=\"198\"><p><b>Autodesk</b></p></td>\n   <td width=\"108\"><p>$59 billion</p></td>\n   <td>28.8%</td>\n   <td width=\"102\">4.1%</td>\n   <td width=\"108\">(11.7%)</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>9</p></td>\n   <td width=\"198\"><p><b>Qualcomm</b></p></td>\n   <td width=\"108\"><p>$200 billion</p></td>\n   <td>25.6%</td>\n   <td width=\"102\">3.9%</td>\n   <td width=\"108\">19.1%</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>10</p></td>\n   <td width=\"198\"><p><b>Tencent Holdings</b></p></td>\n   <td width=\"108\"><p>$545 billion</p></td>\n   <td>3.7%</td>\n   <td width=\"102\"><p>3.9%</p></td>\n   <td width=\"108\">(20.8%)</td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>Total Top 10</p></td>\n   <td width=\"198\"><p>N/A</p></td>\n   <td width=\"108\"><p>N/A</p></td>\n   <td>N/A</td>\n   <td width=\"102\"><p>58.7%</p></td>\n   <td width=\"108\"><p>N/A</p></td>\n  </tr>\n  <tr>\n   <td width=\"101\"><p>N/A</p></td>\n   <td width=\"198\"><p><b>S&amp;P 500</b> / <b>Nasdaq Composite Indexes</b></p></td>\n   <td width=\"108\"><p>N/A</p></td>\n   <td>N/A</td>\n   <td width=\"102\"><p>N/A</p></td>\n   <td width=\"108\">26% / 17.8%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data sources: Roundhill Ball Metaverse ETF, Yahoo! Finance, and YCharts. EPS = earnings per share. YTD = year to date. *Roblox went public via a direct listing on March 10, 2021; its stock is up 47.6% from the opening price on the first trading day. Data to Dec. 16, 2021.</p>\n<p>Below is a brief look at how the top five companies in this ETF are involved in the metaverse.</p>\n<p>Nvidia is a \"pick-and-shovel\" play on the metaverse. That is, the computer gaming and tech giant provides the tools other companies need to create their own metaverses. Most notable among these tools is its recently launched Omniverse platform. The \"Omniverse brings together Nvidia's expertise in AI [artificial intelligence], simulation, graphics, and computing infrastructure,\" CEO Jensen Huang said last month in the company's release of its stellar fiscal third-quarter results.</p>\n<p>Roblox (No. 2) and Unity Software (No. 5) are gaming engines that can be used to create virtual worlds. They're both relatively new to the public markets: Roblox went public in March 2021 via a direct listing on the New York Stock Exchange and Unity held its initial public offering (IPO) in September 2020. Both companies are rapidly growing revenue, but neither is profitable from an accounting standpoint.</p>\n<p>Microsoft has been building Mesh, its mixed-reality platform that will power Microsoft Teams and other applications. Users will be able to access Mesh on the company's enterprise-focused augmented-reality headset HoloLens 2, as well as virtual reality (VR) headsets, mobile phones, tablets, or PCs using any Mesh-enabled app.</p>\n<p>Last week, Meta Platforms took its first leap into the metaverse via its public launch of Horizon Worlds to adults in the U.S. and Canada. Horizon Worlds is a free social VR platform in which users equipped with the company's Oculus Quest 2 VR headsets can interact.</p>\n<h2>A solid way to invest in the metaverse</h2>\n<p>The Roundhill Ball Metaverse ETF looks like a solid way for investors to get exposure to the metaverse. The drawback of ETFs is the same as their advantage: diversification. Indeed, investors willing to do some work and select individual stocks should have a decent shot at outperforming this fund.</p>\n<p>If you're looking for a larger company that's profitable, it's probably hard to go wrong with Nvidia, Microsoft, Amazon, or Apple. Meta Platforms (the former Facebook) isn't as good a bet. It has higher regulatory risk than the other big U.S.-based tech companies, in my view. Moreover, it has nearly all its (revenue) eggs in one basket because it generates almost all of its revenue from digital advertising.</p>\n<p>Risk-averse investors should steer clear of Tencent Holdings because it's headquartered in China. The Chinese government has been cracking down on tech companies, making their regulatory risk high.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top 10 Metaverse Stocks in META, the World's First Metaverse ETF</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop 10 Metaverse Stocks in META, the World's First Metaverse ETF\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 22:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/invest-in-metaverse-stocks-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors are abuzz about the metaverse. This term catapulted into the mainstream in late October when the social media giant formerly known as Facebook announced it was changing its corporate name to...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/invest-in-metaverse-stocks-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4538":"云计算","BK4527":"明星科技股","BK4543":"AI","NVDA":"英伟达","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4141":"半导体产品","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","U":"Unity Software Inc.","BK4097":"系统软件","BK4547":"WSB热门概念","MSFT":"微软","BK4085":"互动家庭娱乐","BK4504":"桥水持仓","BK4549":"软银资本持仓","BK4548":"巴美列捷福持仓","BK4565":"NFT概念","BK4529":"IDC概念","BK4528":"SaaS概念","VR":"GLOBAL X METAVERSE ETF","BK4516":"特朗普概念","BK4023":"应用软件","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","RBLX":"Roblox Corporation","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4524":"宅经济概念","BK4567":"ESG概念","BK4535":"淡马锡持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4525":"远程办公概念","IPO":"Renaissance IPO ETF","BK4566":"资本集团","BK4508":"社交媒体"},"source_url":"https://www.fool.com/investing/2021/12/17/invest-in-metaverse-stocks-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192597562","content_text":"Investors are abuzz about the metaverse. This term catapulted into the mainstream in late October when the social media giant formerly known as Facebook announced it was changing its corporate name to Meta Platforms (NASDAQ:FB) to reflect its focus on the metaverse.\nThe metaverse, which is essentially a melding of the physical and virtual worlds, is widely viewed as the next evolution of the internet. Market size projections for the metaverse vary widely, so suffice it to say this space is poised to be massive.\nLet's take a look at the Roundhill Ball Metaverse ETF (NYSEMKT:META), the world's first metaverse exchange-traded fund (ETF). You might decide that one or more of this ETF's holdings are worth further exploration or that you want to buy the ETF itself.\nRoundhill Ball Metaverse ETF: Performance and the basics\nThis ETF only began trading on June 30, 2021, so it's too soon to make any judgments about its performance. That said, since its inception, it's down 2.1% through Dec. 16. This performance lags that of the broader market, as the S&P 500 index has returned 9.5% and the tech-heavy Nasdaq Composite has gained 4.7% over this period.\nThe Roundhill Ball Metaverse ETF is an index fund that's designed to track the performance of the Ball Metaverse Index, which consists of a portfolio of worldwide companies involved in the metaverse. It had 40 holdings as of Dec. 16. The fund is rebalanced quarterly and has an expense ratio of 0.75%, which is moderately reasonable.\nThis ETF is far from a pure play on the metaverse, as its holdings are mostly huge companies that are involved in multiple businesses.\nRoundhill Ball Metaverse ETF: Top 10 stock holdings\n\n\n\nHolding No. \n Company\nMarket Cap \nWall Street's Projected Annualized EPS Growth Over Next 5 Years\nWeight (% of Portfolio)\nYTD 2021 Return \n\n\n\n\n\n1\nNvidia (NASDAQ:NVDA)\n$710 billion\n39.4%\n10.6%\n118%\n\n\n2\nRoblox (NYSE:RBLX)\n$55 billion\nN/A\n8.6%\nN/A*\n\n\n3\nMicrosoft (NASDAQ:MSFT)\n$2.4 trillion\n16.5%\n7.7%\n47.3%\n\n\n4\nMeta Platforms\n$932 billion\n21.4%\n6.6%\n22.6%\n\n\n5\nUnity Software (NYSE:U)\n$38 billion\nN/A\n4.9%\n(13%)\n\n\n6\nApple\n$2.8 trillion\n15.7%\n4.2%\n30.6%\n\n\n7\nAmazon.com\n$1.7 trillion\n36%\n4.2%\n3.7%\n\n\n8\nAutodesk\n$59 billion\n28.8%\n4.1%\n(11.7%)\n\n\n9\nQualcomm\n$200 billion\n25.6%\n3.9%\n19.1%\n\n\n10\nTencent Holdings\n$545 billion\n3.7%\n3.9%\n(20.8%)\n\n\nTotal Top 10\nN/A\nN/A\nN/A\n58.7%\nN/A\n\n\nN/A\nS&P 500 / Nasdaq Composite Indexes\nN/A\nN/A\nN/A\n26% / 17.8%\n\n\n\nData sources: Roundhill Ball Metaverse ETF, Yahoo! Finance, and YCharts. EPS = earnings per share. YTD = year to date. *Roblox went public via a direct listing on March 10, 2021; its stock is up 47.6% from the opening price on the first trading day. Data to Dec. 16, 2021.\nBelow is a brief look at how the top five companies in this ETF are involved in the metaverse.\nNvidia is a \"pick-and-shovel\" play on the metaverse. That is, the computer gaming and tech giant provides the tools other companies need to create their own metaverses. Most notable among these tools is its recently launched Omniverse platform. The \"Omniverse brings together Nvidia's expertise in AI [artificial intelligence], simulation, graphics, and computing infrastructure,\" CEO Jensen Huang said last month in the company's release of its stellar fiscal third-quarter results.\nRoblox (No. 2) and Unity Software (No. 5) are gaming engines that can be used to create virtual worlds. They're both relatively new to the public markets: Roblox went public in March 2021 via a direct listing on the New York Stock Exchange and Unity held its initial public offering (IPO) in September 2020. Both companies are rapidly growing revenue, but neither is profitable from an accounting standpoint.\nMicrosoft has been building Mesh, its mixed-reality platform that will power Microsoft Teams and other applications. Users will be able to access Mesh on the company's enterprise-focused augmented-reality headset HoloLens 2, as well as virtual reality (VR) headsets, mobile phones, tablets, or PCs using any Mesh-enabled app.\nLast week, Meta Platforms took its first leap into the metaverse via its public launch of Horizon Worlds to adults in the U.S. and Canada. Horizon Worlds is a free social VR platform in which users equipped with the company's Oculus Quest 2 VR headsets can interact.\nA solid way to invest in the metaverse\nThe Roundhill Ball Metaverse ETF looks like a solid way for investors to get exposure to the metaverse. The drawback of ETFs is the same as their advantage: diversification. Indeed, investors willing to do some work and select individual stocks should have a decent shot at outperforming this fund.\nIf you're looking for a larger company that's profitable, it's probably hard to go wrong with Nvidia, Microsoft, Amazon, or Apple. Meta Platforms (the former Facebook) isn't as good a bet. It has higher regulatory risk than the other big U.S.-based tech companies, in my view. Moreover, it has nearly all its (revenue) eggs in one basket because it generates almost all of its revenue from digital advertising.\nRisk-averse investors should steer clear of Tencent Holdings because it's headquartered in China. The Chinese government has been cracking down on tech companies, making their regulatory risk high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":920,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693025341,"gmtCreate":1639939247109,"gmtModify":1639939247235,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Please huat nova.&nbsp;","listText":"Please huat nova.&nbsp;","text":"Please huat nova.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693025341","repostId":"2192905514","repostType":4,"repost":{"id":"2192905514","kind":"highlight","pubTimestamp":1639855524,"share":"https://www.laohu8.com/m/news/2192905514?lang=&edition=full","pubTime":"2021-12-19 03:25","market":"us","language":"en","title":"Biden to deliver Tuesday speech on Omicron variant amid COVID rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2192905514","media":"reuters.com","summary":"(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant","content":"<p>(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported&nbsp;on Saturday, citing a White House official.</p>\n<p>Biden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden to deliver Tuesday speech on Omicron variant amid COVID rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden to deliver Tuesday speech on Omicron variant amid COVID rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>reuters.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported on Saturday, citing a White House official.\nBiden is expected...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192905514","content_text":"(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported on Saturday, citing a White House official.\nBiden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699706015,"gmtCreate":1639886846944,"gmtModify":1639886847065,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Nova!!!!","listText":"Nova!!!!","text":"Nova!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/699706015","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","ARNA":"阿里那","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","CERN":"美国塞纳","PFE":"辉瑞","ORCL":"甲骨文"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699454604,"gmtCreate":1639881638280,"gmtModify":1639881638376,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","listText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","text":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699454604","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p>\n<p>Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p>\n<p><img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p>\n<p>So what</p>\n<p><b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p>\n<p>Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p>\n<p>\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p>\n<p>As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p>\n<p>\"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p>\n<p>Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p>\n<p>Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p>\n<p>Now what</p>\n<p>Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 13:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690255150,"gmtCreate":1639672141160,"gmtModify":1639672141253,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Good&nbsp;read!","listText":"Good&nbsp;read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690255150","repostId":"1121295991","repostType":4,"repost":{"id":"1121295991","kind":"news","pubTimestamp":1639664163,"share":"https://www.laohu8.com/m/news/1121295991?lang=&edition=full","pubTime":"2021-12-16 22:16","market":"us","language":"en","title":"Why analysts love Apple right now","url":"https://stock-news.laohu8.com/highlight/detail?id=1121295991","media":"Yahoo Finance","summary":"Apple’s  market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for ","content":"<p>Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.</p>\n<p>This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.</p>\n<p>Several factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.</p>\n<p>“We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”</p>\n<p>Apple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.</p>\n<p>“I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.</p>\n<p>Apple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.</p>\n<p>The same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.</p>\n<p>“We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.</p>\n<p>Of course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.</p>\n<p>“Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”</p>\n<p>Taken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.</p>\n<p>“Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”</p>\n<p>“We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”</p>\n<p>Now Apple just has to prove the analysts’ optimism correct.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why analysts love Apple right now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy analysts love Apple right now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121295991","content_text":"Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.\nThis month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.\nSeveral factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.\n“We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”\nApple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.\n“I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.\nApple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.\nThe same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.\n“We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.\nOf course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.\n“Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”\nTaken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.\n“Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”\n“We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”\nNow Apple just has to prove the analysts’ optimism correct.","news_type":1},"isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609123127,"gmtCreate":1638254172838,"gmtModify":1638254172928,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Vaccine stock rally tonight 🔥🙏💉","listText":"Vaccine stock rally tonight 🔥🙏💉","text":"Vaccine stock rally tonight 🔥🙏💉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609123127","repostId":"1141430877","repostType":4,"repost":{"id":"1141430877","kind":"news","pubTimestamp":1638251771,"share":"https://www.laohu8.com/m/news/1141430877?lang=&edition=full","pubTime":"2021-11-30 13:56","market":"us","language":"en","title":"Moderna CEO says vaccines likely less effective against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1141430877","media":"Reuters","summary":"SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be a","content":"<p>SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p>Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p>\n<p>Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p>\n<p>He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p>\n<p>Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says vaccines likely less effective against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says vaccines likely less effective against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 13:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/1-moderna-ceo-says-vaccines-055048321.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141430877","content_text":"SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nVaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.\nBancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.\nHe had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.\nFear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1038,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876551023,"gmtCreate":1637333835298,"gmtModify":1637334091344,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Holding on....especially with the opening of themeparks in the near future.","listText":"Holding on....especially with the opening of themeparks in the near future.","text":"Holding on....especially with the opening of themeparks in the near future.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876551023","repostId":"1157818316","repostType":4,"repost":{"id":"1157818316","kind":"news","pubTimestamp":1637331780,"share":"https://www.laohu8.com/m/news/1157818316?lang=&edition=full","pubTime":"2021-11-19 22:23","market":"us","language":"en","title":"Disney Stock: Jim Cramer Says Selling Now Is Shortsighted","url":"https://stock-news.laohu8.com/highlight/detail?id=1157818316","media":"TheStreet","summary":"For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term ","content":"<p>For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.</p>\n<p>The market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.</p>\n<p>At the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fa43949a100665b5ceb4b8a647ee6f93\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: CNBC's Jim Cramer, host of Mad Money.</span></p>\n<p><b>New content</b></p>\n<p>One key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.</p>\n<p>But Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix&nbsp;spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.</p>\n<p>Therefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.</p>\n<p><b>Theme parks</b></p>\n<p>With the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.</p>\n<p><b>What analysts say</b></p>\n<p>While many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which&nbsp;reiterated&nbsp;its “overweight” rating of Disney:</p>\n<blockquote>\n “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”\n</blockquote>\n<p><b>Our view</b></p>\n<p>We believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.</p>\n<p>In our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney Stock: Jim Cramer Says Selling Now Is Shortsighted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney Stock: Jim Cramer Says Selling Now Is Shortsighted\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-19 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.\nThe market continues to witness softness in ...</p>\n\n<a href=\"https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://www.thestreet.com/streaming/dis/jim-cramer-it-is-shortsighted-to-sell-disney-stock-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157818316","content_text":"For CNBC’s Jim Cramer, investors are buying high and selling low by focusing on Disney’s short-term woes rather than on the company’s long-term potential.\nThe market continues to witness softness in Disney stock. Investors seemed disappointed in last quarter’s results, particularly regarding the addition of Disney+ subscribers.On the day after the earnings report, share price fell 7%.\nAt the same time, other investors have remained optimistic about the company. One such example is CNBC’s Jim Cramer, host of Mad Money, whoseesreasons to bet on DIS for the long term. Among them are (1) the company's new content investments, (2) the reopening of the parks and (3) the contrarian view in the face of so much negative sentiment.\nFigure 1: CNBC's Jim Cramer, host of Mad Money.\nNew content\nOne key criticism of Disney’s streaming business model are the high costs. The DTC (direct-to-consumer) approach entails large expenses with the production of exclusive content, which is arguably key in attracting and retaining the platform's subscribers.\nBut Cramer does not seem to view this as a problem, rather as a long-term investment that the market still misunderstands. Disney and peers like Netflix spend a large chunk of their operating income on content production, which often scares off investors and sends them to the exits. But after the content is available and it helps to drive new subscriptions, investors return to buy back the shares when the herd chooses to do the same.\nTherefore, by focusing on the short term and ignoring the long term, many investors continue to buy high and sell low – a recipe for disaster over time.\nTheme parks\nWith the reopening of Disney's parks, the company’s financial results should start to resemble those of the pre-pandemic period. Therefore, looking only at the new streaming segment is a bit narrow, as it still represents a small slice of Disney’s revenue – although probably the fastest growing over the long haul.\nWhat analysts say\nWhile many investors remain pessimistic about DIS, many investment banks continue to view the company's long-term growth potential as appealing. This is the case of Morgan Stanley, which reiterated its “overweight” rating of Disney:\n\n “We continue to believe its guidance is achievable, that with streaming scale comes substantial earnings power, and that success is not priced in.”\n\nOur view\nWe believe that Disney is still a major player in the so-called streaming wars, and one of the few that can effectively compete for market share with companies like Netflix and Amazon. Therefore, a smaller-than-expected addition of users in a single quarter, especially at an inflection point in the COVID-19 crisis, should not be extrapolated too far out into the future.\nIn our view, one must wait for a series of quarterly reports to understand how Disney+ may fare against its peers. Growth concerns should only come, if at all, after careful analysis of the longer-term trend.","news_type":1},"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878704212,"gmtCreate":1637228338741,"gmtModify":1637228338741,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Finally!!! Its time for it to shine!","listText":"Finally!!! Its time for it to shine!","text":"Finally!!! Its time for it to shine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878704212","repostId":"1168434077","repostType":4,"isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889762920,"gmtCreate":1631180128360,"gmtModify":1631890825358,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","text":"$Tiger Brokers(TIGR)$waiting for report to be released tmr. Hang in there! [吃瓜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889762920","isVote":1,"tweetType":1,"viewCount":530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889766003,"gmtCreate":1631180027002,"gmtModify":1631883559823,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","text":"$Tesla Motors(TSLA)$[财迷]","images":[{"img":"https://static.tigerbbs.com/8e5acacbd5f146c0a6a10d8c719c1a46","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889766003","isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":812596013,"gmtCreate":1630593348932,"gmtModify":1631890825361,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","text":"$Tesla Motors(TSLA)$[财迷]","images":[{"img":"https://static.tigerbbs.com/791513175bb9ae21643cb6611407a8ed","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812596013","isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":812591614,"gmtCreate":1630593284338,"gmtModify":1631890825364,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"More more more","listText":"More more more","text":"More more more","images":[{"img":"https://static.tigerbbs.com/a912fe82c31f2472f4a003b31133e397","width":"720","height":"2143"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812591614","isVote":1,"tweetType":1,"viewCount":54,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175649968,"gmtCreate":1627030371954,"gmtModify":1631890825368,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","listText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","text":"$Gaotu Techedu Inc.(GOTU)$Can't even describe how I feel now. :( X 10000000","images":[{"img":"https://static.tigerbbs.com/d93c31f6cedc6d06a9580a18b1e487d3","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":3,"link":"https://laohu8.com/post/175649968","isVote":1,"tweetType":1,"viewCount":1552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":145779375,"gmtCreate":1626250165197,"gmtModify":1631886369705,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>T.T from +25% profit to loss in a week. Ouchhhhhh.","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>T.T from +25% profit to loss in a week. Ouchhhhhh.","text":"$Stem Inc.(STEM)$T.T from +25% profit to loss in a week. Ouchhhhhh.","images":[{"img":"https://static.tigerbbs.com/0b3d4fba36c52eb193d8f62c526f41b0","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145779375","isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121813326,"gmtCreate":1624458389665,"gmtModify":1631886369743,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"$Stem Inc.(STEM)$[财迷] [财迷] [财迷]","images":[{"img":"https://static.tigerbbs.com/6b98ef2191be4e3fe8f302cee4c12644","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121813326","isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":163644616,"gmtCreate":1623884735035,"gmtModify":1631885748217,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>lets do it!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>lets do it!&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$lets do it!","images":[{"img":"https://static.tigerbbs.com/950bf86affe4ceeb525c4cd4d4f5ab35","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163644616","isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":116796288,"gmtCreate":1622818075944,"gmtModify":1631890825371,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Let's go!","listText":"Let's go!","text":"Let's go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/116796288","repostId":"116443496","repostType":1,"repost":{"id":116443496,"gmtCreate":1622816867715,"gmtModify":1631884132357,"author":{"id":"3580359170890697","authorId":"3580359170890697","name":"ahong2706","avatar":"https://static.tigerbbs.com/0016ddf5c57401a3852f07709daabd2a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580359170890697","authorIdStr":"3580359170890697"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$</a>Green Tea Frap x)","listText":"<a href=\"https://laohu8.com/S/VOO\">$Vanguard S&amp;P 500 ETF(VOO)$</a>Green Tea Frap x)","text":"$Vanguard S&P 500 ETF(VOO)$Green Tea Frap x)","images":[{"img":"https://static.tigerbbs.com/e778f7ee341383ddc105cc95b3200821","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/116443496","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":175649968,"gmtCreate":1627030371954,"gmtModify":1631890825368,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","listText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>Can't even describe how I feel now. :( X 10000000","text":"$Gaotu Techedu Inc.(GOTU)$Can't even describe how I feel now. :( X 10000000","images":[{"img":"https://static.tigerbbs.com/d93c31f6cedc6d06a9580a18b1e487d3","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":3,"link":"https://laohu8.com/post/175649968","isVote":1,"tweetType":1,"viewCount":1552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":878704212,"gmtCreate":1637228338741,"gmtModify":1637228338741,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Finally!!! Its time for it to shine!","listText":"Finally!!! Its time for it to shine!","text":"Finally!!! Its time for it to shine!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/878704212","repostId":"1168434077","repostType":4,"repost":{"id":"1168434077","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637227046,"share":"https://www.laohu8.com/m/news/1168434077?lang=&edition=full","pubTime":"2021-11-18 17:17","market":"us","language":"en","title":"Novavax shares jumped 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1168434077","media":"Tiger Newspress","summary":"Novavax shares jumped 5% in premarket trading as EU decision on Novavax COVID-19 shot could come 'wi","content":"<p>Novavax shares jumped 5% in premarket trading&nbsp;as&nbsp;EU decision on Novavax COVID-19 shot could come 'within weeks'.</p>\n<p><img src=\"https://static.tigerbbs.com/6082341ff6cf8c02e6284028a5ba5cd6\" tg-width=\"848\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p>\n<p>The European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.</p>\n<p>The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.</p>\n<p>If approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson.</p>\n<p>The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.</p>\n<p>The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.</p>\n<p>Novavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-18 17:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax shares jumped 5% in premarket trading&nbsp;as&nbsp;EU decision on Novavax COVID-19 shot could come 'within weeks'.</p>\n<p><img src=\"https://static.tigerbbs.com/6082341ff6cf8c02e6284028a5ba5cd6\" tg-width=\"848\" tg-height=\"620\" width=\"100%\" height=\"auto\"></p>\n<p>The European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.</p>\n<p>The protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.</p>\n<p>If approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson &amp; Johnson.</p>\n<p>The major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.</p>\n<p>The EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.</p>\n<p>Novavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168434077","content_text":"Novavax shares jumped 5% in premarket trading as EU decision on Novavax COVID-19 shot could come 'within weeks'.\n\nThe European Union’s drug regulator said on Wednesday it could decide on Novavax’s COVID-19 vaccine approval “within weeks” if the data it has received from the drugmaker was sufficient to prove the shot’s effectiveness.\nThe protein-based vaccine, branded Nuvaxovid, has been under a rolling review since February, the European Medicines Agency (EMA) said. Such reviews allow for a speedy approval.\nIf approved by the EMA, the shot would be the region’s fifth coronavirus vaccine, joining those from Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.\nThe major approval could come much ahead of authorisation in the United States, where Novavax had to resolve manufacturing issues and expects to file for approval by the end of the year.\nThe EMA said two of its advisory panels were looking into various plans submitted by Novavax on risk management, and development and studies of the vaccine for use in children.\nNovavax’s shot received its first emergency use approval earlier this month in Indonesia. The company has also sought backing from the World Health Organization. The Philippines on Wednesday authorised emergency use of a version made by India’s Serum Institute.","news_type":1},"isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699706015,"gmtCreate":1639886846944,"gmtModify":1639886847065,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Nova!!!!","listText":"Nova!!!!","text":"Nova!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/699706015","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","ARNA":"阿里那","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","CERN":"美国塞纳","PFE":"辉瑞","ORCL":"甲骨文"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":116799900,"gmtCreate":1622817863200,"gmtModify":1631890825372,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Thank you. Thank you.","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Thank you. Thank you.","text":"$Tiger Brokers(TIGR)$Thank you. Thank you.","images":[{"img":"https://static.tigerbbs.com/57461042d2e8c4ae13af70e98202a45a","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/116799900","isVote":1,"tweetType":1,"viewCount":116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":696300104,"gmtCreate":1640612840415,"gmtModify":1640612840516,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Yes pleaseeeeeee.","listText":"Yes pleaseeeeeee.","text":"Yes pleaseeeeeee.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696300104","repostId":"1111088353","repostType":4,"repost":{"id":"1111088353","kind":"news","pubTimestamp":1640610579,"share":"https://www.laohu8.com/m/news/1111088353?lang=&edition=full","pubTime":"2021-12-27 21:09","market":"us","language":"en","title":"Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=1111088353","media":"Seeking Alpha","summary":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems ","content":"<p><b>Summary</b></p>\n<ul>\n <li>The stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.</li>\n <li>The stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.</li>\n <li>Plug Power shows some important parallels with Tesla, on which I will elaborate in this article.</li>\n <li>If the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80405c7f3988b402597ce18944c15c47\" tg-width=\"1536\" tg-height=\"683\" width=\"100%\" height=\"auto\"><span>http://www.fotogestoeber.de/iStock via Getty Images</span></p>\n<p>How can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.</p>\n<p>In this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).</p>\n<p><b>Great stock performance, but a lofty valuation</b></p>\n<p>Plug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the&nbsp;2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.</p>\n<p>More recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the&nbsp;Build Back Better Plan&nbsp;of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.</p>\n<p>Please review the following charts for illustration of these metrics:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3664f73c0fc1fcd1b2673c8df4701be5\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Plug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)</i></p>\n<p>A true story stock</p>\n<blockquote>\n A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)\n</blockquote>\n<p>A story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.</p>\n<p>Hydrogen is indeed a promising market. Let us explore the&nbsp;potential benefits and promises&nbsp;of hydrogen:</p>\n<ul>\n <li>Green hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.</li>\n <li>Green hydrogen can contribute to improvements in air quality and energy security.</li>\n <li>Hydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.</li>\n <li>Hydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.</li>\n <li>Clean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.</li>\n <li>Currently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.</li>\n</ul>\n<p>As such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.</p>\n<p>Plug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which&nbsp;could transition&nbsp;from a story stock to a large positive cash flow company.</p>\n<p>The commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with&nbsp;Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and&nbsp;Brookfield Renewable(BEP).</p>\n<p><b>Parallels with early-stage Tesla</b></p>\n<p>I think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.</p>\n<p>Let us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9911b4514f3c0a566dffcd28c188e1c\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Tesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)</i></p>\n<p>There are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d46be5e658002b2f45b8c5ca43559b93\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Tesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)</i></p>\n<p>These two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d29232b1b3d9ff99e1edb6e4eac33901\" tg-width=\"635\" tg-height=\"478\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p>\n<p><i>Development of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)</i></p>\n<p>As the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.</p>\n<p>The million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.</p>\n<p>Another similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well&nbsp;in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.</p>\n<p><b>Currently, expectations still beat metrics</b></p>\n<p>Like Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. This<i>could</i>mean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.</p>\n<p><b>These are some very large ifs.</b></p>\n<p>Of course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.</p>\n<p>Plug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.</p>\n<p>Plug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlug Power Trades Like A Story Stock And Smells Like An Early-Stage Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.\nThe stock performance of almost 2,000% over...</p>\n\n<a href=\"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源"},"source_url":"https://seekingalpha.com/article/4476789-plug-power-stock-promising-business-parallels-with-tesla","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111088353","content_text":"Summary\n\nThe stock of Plug Power enjoyed some great appreciation during the last years, which seems hard to explain when purely looking at the fundamentals.\nThe stock performance of almost 2,000% over the last 5 years is an illustration of the increased momentum of the hydrogen market.\nPlug Power shows some important parallels with Tesla, on which I will elaborate in this article.\nIf the sentiment can remain positive while growth continues, short-term fundamentals might not matter much.\n\nhttp://www.fotogestoeber.de/iStock via Getty Images\nHow can a company in a niche sector which has continuously burned cash over the years have a market capitalization of over $17B? Plug Power (PLUG) is a pure-play hydrogen company that has yet to run a profit. Still, the stock has returned a total of almost 2,000% over the last 5 years.\nIn this article, I will investigate the promises and expectations behind Plug Power and compare the stock to another stock with large promises: Tesla (TSLA).\nGreat stock performance, but a lofty valuation\nPlug Power has behaved somewhat like a battleground stock during the last couple of years. Ever since the 2014 hydrogen rally, Plug Power has remained a stock that lured investors who believe in the technology, but also attracted quite some short-sellers, judged by its current short interest of almost 10 percent.\nMore recently, the stock has experienced a huge liftoff, most likely fueled by the announcement of the Build Back Better Plan of president Biden. Since then, Plug Power's stock more or less came back to earth again, even though it is still trading at a very high price to sales ratio.\nPlease review the following charts for illustration of these metrics:\nData by YCharts\nPlug Power development of share price, short interest, and price to sales ratio during the last 10 years. (source: YCharts)\nA true story stock\n\n A story stock refers to a company's shares whose value reflects expected outperformance, the culmination of some new innovation, or favorable press coverage, rather than its market value being solely based on fundamentals like assets and income (Source:Investopedia)\n\nA story can be a powerful backbone of stock performance. Though the hydrogen market is still somewhat of a niche, the story of Plug is one of great expectations.\nHydrogen is indeed a promising market. Let us explore the potential benefits and promises of hydrogen:\n\nGreen hydrogen can help to decarbonize multiple sectors in which it is difficult to reduce emissions, like long-haul transport, chemical industry, and iron and steel production.\nGreen hydrogen can contribute to improvements in air quality and energy security.\nHydrogen can be produced using a multitude of sources, such as renewables, nuclear energy, natural gas, oil, and even coal. Transportation can be done using pipelines or in liquefied form. It can be transformed into electricity very easily.\nHydrogen can play an important role in coping with the variable outputs of renewable energy sources. Wind and solar energy output are not always in sync with electricity demand, and hydrogen can be used as a store or energy in times when renewable energy production outpaces demand. These storages can be used in times when renewable energy output is lower than demand, and can be saved for days, weeks, or even months, and can even be transported over long distances if needed.\nClean hydrogen is currently used in an expanding number of projects worldwide, and it seems to be a matter of time before the technology is scaled up and costs are brought down.\nCurrently, hydrogen is mostly used in oil refining processes and for the production of fertilizers. Sectors in which it is still hardly used, like transport, buildings, and power generation seem large untapped markets.\n\nAs such, hydrogen could play an important supporting role in the renewable energy transition, supplying markets that are difficult or impractical to reach for batteries.\nPlug Power has a focused strategy, is already an established business in the hydrogen market, and has a large growing number of commercial relationships. This might mean that the company has the potential to become one of the first pure-play hydrogen companies which could transition from a story stock to a large positive cash flow company.\nThe commercial relationships and collaborations which Plug is undertaking are among the most important future drivers of growth for the company, among which are collaborations with Airbus(OTCPK:EADSF),Phillips66(PSX),Acciona(OTCPK:ACXIF),BAE Systems(OTCPK:BAESF),Baker Hughes(BKR), and Brookfield Renewable(BEP).\nParallels with early-stage Tesla\nI think it is very interesting to compare Plug Power with Tesla. This seems to make sense since they were both one of the largest first movers in big markets: EV for Tesla and hydrogen for Plug. Tesla also was (and might still be) a good example of a story stock, with their large promises of electrifying the automotive sector.\nLet us look at the share price development, short percentage, and PS ratio of Tesla during the period from 2010 to the end of 2019:\nData by YCharts\nTesla's development of share price, short interest, and price to sales ratio between 2010 and the end of 2019. (source: YCharts)\nThere are some noticeable differences between the share price development of Plug Power and an earlier-stage Tesla. First of all, from 2012 to 2019, the percentage of Tesla's stock sold short has consistently oscillated around 20%. Plug Power is already under 10% and has moved around 15% for the largest part of the last couple of years. But the biggest difference between the two stocks is probably that the price to sales ratio of Tesla has trended down quickly between 2010 and the end of 2019. Since Plug Power's price to sales ratio is heavily influenced by its recent outlier, let us take a look at a graph comparing the two between 2010 and September of this year:\nData by YCharts\nTesla and Plug Power development price to sales ratio between 2010 and September 2021. (source: YCharts)\nThese two ratios look to have a lot more in common. But as we can already see, after the end of 2019, Tesla's price to sales ratio went sharply up again. The reason for this was, of course, the almost unprecedented skyrocketing of the Tesla stock starting from the end of 2019. This is illustrated in the following graph of what happened to Tesla shares from September 2019 until now:\nData by YCharts\nDevelopment of Tesla share price, short interest, and price to sales ratio between September 2019 and now. (source: YCharts)\nAs the stock price of Tesla skyrocketed, the short percentage went down sharply and the PS ratio went up.\nThe million-dollar question is of course, could this happen to Plug Power as well? Technically, if we look solely at the metrics of Plug compared with the metrics of Tesla just before the stock price exploded, the P/S ratio of Plug is still much too high to expect that the stock could go in the same direction in short order. I also believe that fundamentally, Plug would need to experience some serious growth for the stock to be able to regain its recent upward momentum.\nAnother similarity between Plug and Tesla is that negative earnings surprises have been many at Plug recently, this happened to Tesla as well in 2019. At the time, Tesla's stock price was not negatively impacted by those surprises. Currently, the market seems to shake off Plug Power's results as well, though the stock did drop by more than 50% since last year.\nCurrently, expectations still beat metrics\nLike Tesla, Plug's share price seems to be governed more by growth expectations than by current stock metrics. Thiscouldmean that Plug would be able to go in the same direction as Tesla if enough investors remain convinced that their business model is profitable for the future and if growth can be expected to continue. Also, as for Tesla, in the long term, fundamental metrics will need to correspond with their lofty valuations. This means that the companies will need to deliver on their expectations.\nThese are some very large ifs.\nOf course, the hydrogen market is different from the EV market. Since the energy density of hydrogen is very high, it will likely be able to compete in markets where batteries still have issues, like long-haul transport. On the other hand, on an energy efficiency level, batteries have some large benefits over hydrogen for smaller transport purposes. On aggregate, I am skeptical about hydrogen being able to be a strong competitor in the EV space, but it will likely play a large role in other modes of transport, as in energy storage.\nPlug Power has been trading like a stock for believers, which shows some strong parallels with Tesla. Theoretically, the stock could follow the same direction as Tesla did, but this is anyone's guess and I believe it would take more growth to continue its upward momentum.\nPlug Power is a promising business, but the company had some bad results recently. This did not impact the stock much during the last 2 years. In the short term, the stock price seems to be most impacted by sentiment and not by fundamentals. This makes it a wonderful stock for traders, but as a long-term investor, I am staying on the sidelines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609123127,"gmtCreate":1638254172838,"gmtModify":1638254172928,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Vaccine stock rally tonight 🔥🙏💉","listText":"Vaccine stock rally tonight 🔥🙏💉","text":"Vaccine stock rally tonight 🔥🙏💉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609123127","repostId":"1141430877","repostType":4,"isVote":1,"tweetType":1,"viewCount":1038,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":121813326,"gmtCreate":1624458389665,"gmtModify":1631886369743,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"$Stem Inc.(STEM)$[财迷] [财迷] [财迷]","images":[{"img":"https://static.tigerbbs.com/6b98ef2191be4e3fe8f302cee4c12644","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121813326","isVote":1,"tweetType":1,"viewCount":517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":876551023,"gmtCreate":1637333835298,"gmtModify":1637334091344,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Holding on....especially with the opening of themeparks in the near future.","listText":"Holding on....especially with the opening of themeparks in the near future.","text":"Holding on....especially with the opening of themeparks in the near future.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/876551023","repostId":"1157818316","repostType":4,"isVote":1,"tweetType":1,"viewCount":857,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889762920,"gmtCreate":1631180128360,"gmtModify":1631890825358,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>waiting for report to be released tmr. Hang in there!&nbsp;[吃瓜]&nbsp;","text":"$Tiger Brokers(TIGR)$waiting for report to be released tmr. Hang in there! [吃瓜]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889762920","isVote":1,"tweetType":1,"viewCount":530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699454604,"gmtCreate":1639881638280,"gmtModify":1639881638376,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","listText":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","text":"Probably due to booster not 'good' enough for omi? Wait for march 2022 for their new shot?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699454604","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p>\n<p>Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p>\n<p><img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p>\n<p>So what</p>\n<p><b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p>\n<p>Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p>\n<p>\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p>\n<p>As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p>\n<p>\"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p>\n<p>Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p>\n<p>Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p>\n<p>Now what</p>\n<p>Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 13:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":812596013,"gmtCreate":1630593348932,"gmtModify":1631890825361,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","text":"$Tesla Motors(TSLA)$[财迷]","images":[{"img":"https://static.tigerbbs.com/791513175bb9ae21643cb6611407a8ed","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812596013","isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":145779375,"gmtCreate":1626250165197,"gmtModify":1631886369705,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>T.T from +25% profit to loss in a week. Ouchhhhhh.","listText":"<a href=\"https://laohu8.com/S/STEM\">$Stem Inc.(STEM)$</a>T.T from +25% profit to loss in a week. Ouchhhhhh.","text":"$Stem Inc.(STEM)$T.T from +25% profit to loss in a week. Ouchhhhhh.","images":[{"img":"https://static.tigerbbs.com/0b3d4fba36c52eb193d8f62c526f41b0","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145779375","isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":698145843,"gmtCreate":1640327029733,"gmtModify":1640327659820,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Another great yr for pfizer!?","listText":"Another great yr for pfizer!?","text":"Another great yr for pfizer!?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698145843","repostId":"1110395878","repostType":4,"repost":{"id":"1110395878","kind":"news","pubTimestamp":1640310818,"share":"https://www.laohu8.com/m/news/1110395878?lang=&edition=full","pubTime":"2021-12-24 09:53","market":"us","language":"en","title":"Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1110395878","media":"Barrons","summary":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over","content":"<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p>\n<p>The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p>\n<p>The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p>\n<p>The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p>\n<p>As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p>\n<p>Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.</p>\n<p>And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.</p>\n<p>The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p>\n<p>The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p>\n<p>Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 09:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used ...</p>\n\n<a href=\"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110395878","content_text":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.\nThe Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.\nThe authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.\nAs Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.\nInvestors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.\nAnd the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.\nThe good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.\nThe FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.\nEarlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.","news_type":1},"isVote":1,"tweetType":1,"viewCount":729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698142420,"gmtCreate":1640326890164,"gmtModify":1640327613911,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Yes. Continue to rallllllyyyyy","listText":"Yes. Continue to rallllllyyyyy","text":"Yes. Continue to rallllllyyyyy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698142420","repostId":"1183390970","repostType":4,"isVote":1,"tweetType":1,"viewCount":1011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690255150,"gmtCreate":1639672141160,"gmtModify":1639672141253,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Good&nbsp;read!","listText":"Good&nbsp;read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690255150","repostId":"1121295991","repostType":4,"repost":{"id":"1121295991","kind":"news","pubTimestamp":1639664163,"share":"https://www.laohu8.com/m/news/1121295991?lang=&edition=full","pubTime":"2021-12-16 22:16","market":"us","language":"en","title":"Why analysts love Apple right now","url":"https://stock-news.laohu8.com/highlight/detail?id=1121295991","media":"Yahoo Finance","summary":"Apple’s  market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for ","content":"<p>Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.</p>\n<p>This month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.</p>\n<p>Several factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.</p>\n<p>“We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”</p>\n<p>Apple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.</p>\n<p>“I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.</p>\n<p>Apple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.</p>\n<p>The same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.</p>\n<p>“We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.</p>\n<p>Of course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.</p>\n<p>“Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”</p>\n<p>Taken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.</p>\n<p>“Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”</p>\n<p>“We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”</p>\n<p>Now Apple just has to prove the analysts’ optimism correct.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why analysts love Apple right now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy analysts love Apple right now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://finance.yahoo.com/news/why-analysts-love-apple-right-now-140655190.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121295991","content_text":"Apple’s (AAPL) market capitalization is once again closing in on $3 trillion. If and when it hits the mark, which will require shares to reach $182.86, Apple will be in historic territory. And analysts are loving it.\nThis month alone, Katy Huberty of Morgan Stanley, Samik Chatterjee of JPMorgan, and Amit Daryanani of Evercore ISI have raised their price targets on the stock to $200. And on Tuesday BofA Global Research’s Wamsi Mohan upgraded the stock from neutral to buy and raised his price target for shares to $210.\nSeveral factors are spurring analysts to fawn over Apple: Optimism for Apple’s iPhone, its coming products including its rumored AR/VR headset, and the company’s ability to suck in consumers and keep them there through its services business.\n“We expect Apple to introduce an augmented reality/virtual reality (AR/VR) headset, either by the end of 2022 or early 2023,” Mohan wrote in a recent analyst note. “We view this technology as a game-changer as it will enable many new applications which will require high performance hardware and higher access speeds.”\nApple’s AR/VR headset,according to Bloomberg’s Mark Gurman, could cost upwards of $3,000 and be geared to gaming, entertainment, and communications. The headset has been rumored for some time, with Apple filing various patents related to the technology.\n“I think what a number of people and investors are thinking about is, ‘Hey, if they move to the glasses, the AR and VR glasses that a lot of people expect to see in '22, that's another opportunity to really build on this incredible ecosystem of device owners, and iOS, and Mac OS holders that really love their devices,’ ” TECHnalysis Research president Bob O’Donnell told Yahoo Finance Live.\nApple’s Services business, which includes its App Store, is one of the major sticking points the company has going for it. After all, if you own an iPhone, you’re going to buy apps, and when it’s time to get a new phone you’ll likely buy another iPhone to keep those apps.\nThe same idea would apply to the company’s AR/VR headset if Apple can wrangle the kind of third-party developer support it already enjoys on the iPhone.\n“We see the potential for more Services monetization relative to iPad as use cases develop beyond gaming and remote servicing and evolve into a whole new way in which the world digitally interacts, which AR/VR experts we've spoken with view as the long-term killer AR/VR application,” Huberty wrote in a Dec. 7 analyst note.\nOf course, Apple’s iPhone is still the major driver of Apple’s revenue. And despite the supply chain problems that have upended nearly every industry around the world, Apple seems to be coming out of the crunch.\n“Our checks indicate iPhone production is surprising to the upside as Apple hasn't experienced the same level of manufacturing disruptions as in the September quarter,” Huberty wrote. “While upward trending COVID cases are worth monitoring given they could create new production bottlenecks, we view supply upside as a driver of better December quarter iPhone results.”\nTaken together, it’s clear analysts believe Apple’s new headset and related apps and services business, not to mention the iPhone, will serve as the catalysts that will not only push Apple over the $3 trillion mark, but send the company’s stock even higher.\n“Apple's rise is testament to its strong business model,” Santosh Rao, Manhattan Venture Partners’ head of research, told Yahoo Finance Live. “It's an amazing story.”\n“We have the cars coming up down the road, the 5G refresh, and so many other things, the services business, of course, is very strong,” he said. “So overall combined, this is a company that's well situated.”\nNow Apple just has to prove the analysts’ optimism correct.","news_type":1},"isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693025877,"gmtCreate":1639939479267,"gmtModify":1639939479362,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Bookmark this","listText":"Bookmark this","text":"Bookmark this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693025877","repostId":"2192597562","repostType":4,"isVote":1,"tweetType":1,"viewCount":920,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693025341,"gmtCreate":1639939247109,"gmtModify":1639939247235,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"Please huat nova.&nbsp;","listText":"Please huat nova.&nbsp;","text":"Please huat nova.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693025341","repostId":"2192905514","repostType":4,"repost":{"id":"2192905514","kind":"highlight","pubTimestamp":1639855524,"share":"https://www.laohu8.com/m/news/2192905514?lang=&edition=full","pubTime":"2021-12-19 03:25","market":"us","language":"en","title":"Biden to deliver Tuesday speech on Omicron variant amid COVID rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2192905514","media":"reuters.com","summary":"(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant","content":"<p>(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported&nbsp;on Saturday, citing a White House official.</p>\n<p>Biden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden to deliver Tuesday speech on Omicron variant amid COVID rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden to deliver Tuesday speech on Omicron variant amid COVID rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>reuters.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported on Saturday, citing a White House official.\nBiden is expected...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192905514","content_text":"(Reuters) - U.S. President Joe Biden will deliver a speech on Tuesday addressing the Omicron variant of the coronavirus, NBC News reported on Saturday, citing a White House official.\nBiden is expected to go beyond his \"Winter Plan\" with additional steps to help communities in need, the report said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889766003,"gmtCreate":1631180027002,"gmtModify":1631883559823,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>[财迷]&nbsp;","text":"$Tesla Motors(TSLA)$[财迷]","images":[{"img":"https://static.tigerbbs.com/8e5acacbd5f146c0a6a10d8c719c1a46","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889766003","isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":812591614,"gmtCreate":1630593284338,"gmtModify":1631890825364,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"More more more","listText":"More more more","text":"More more more","images":[{"img":"https://static.tigerbbs.com/a912fe82c31f2472f4a003b31133e397","width":"720","height":"2143"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812591614","isVote":1,"tweetType":1,"viewCount":54,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163644616,"gmtCreate":1623884735035,"gmtModify":1631885748217,"author":{"id":"3574086622886620","authorId":"3574086622886620","name":"rocketchoo2","avatar":"https://static.tigerbbs.com/e200608974e9d7fd71c2c66492464127","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574086622886620","authorIdStr":"3574086622886620"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>lets do it!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>lets do it!&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$lets do it!","images":[{"img":"https://static.tigerbbs.com/950bf86affe4ceeb525c4cd4d4f5ab35","width":"720","height":"1280"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163644616","isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}